Glycosylated haemoglobins and weights were recorded for 200 consecutive diabetic clinic attenders seen yearly for 5 years, 76 of whom were also seen up to 10 years from diagnosis of type 2 diabetes, representing 1380 patient years.
INTRODUCTION
The prevalence of type 2 diabetes is increasing in the prosperous Western communities of the Northern Hemisphere. This trend and its sequelae are believed to relate particularly to obesityl-', We were interested to determine whether various complications seen 5/ 10 years after diagnosis related to glycaemic control during that period as has been found for retinopathy in type 2 diabetes 3 -5 , whether weight influenced the prevalence of complications and whether increases in hypertension and macrovascular complications related to weight fluctuation as suggested by the Framingham study findings 6 . Prospective records have been kept of weight, of clinical examination for diabetic complications and of glycosylated haemoglobin levels at annual clinical reviews in our diabetic clinics since 1979 7 with 85-95% compliance by clinic staff. We were therefore able to examine the relationship of glycaemic control to complication rates at current annual review 5 years or 10 years from diagnosis. 
England
It Is with regret that we have to record that Dr J Tsoumanis died in 1995
METHODS
The clinical records of 200 consecutive diabetic clinic attenders whose type 2 (non-insulin dependent) diabetes had been diagnosed at the clinic and reviewed annually for 5 years or for 10 years were examined. Age, sex, initial height, weight at diagnosis and at 1, 2, 5 and 10 years, glycosylated haemoglobin (HbA1) levels at 1-5 years in all patients and 6-10 years in 76 of the patients and the current findings (at 5/ 10 year annual review) for albuminuria, peripheral vascular disease, neuropathy, blood pressure and degree of retinopathy (see Appendix 1 for clinical definitions), together with current waist and hip size, serum creatinine and C-peptide levels (1-2 h after food) were recorded.
Glycosylated haemoglobin levels (HbA 1 a+b+c) were measured (as per cent of total haemoglobin) by mini-column chromatography pre 1983 8 , and by electroendosmosis thereafter", after decay of Schiff products. Pre-1983 levels were transformed to electroendosmotic levels (normal values < 8.5%), with which there was a linear relationship, for analysis by a correction of -1.5 using data from parallel assays carried out on 250 samples before the introduction of the latter assay [Coefficient of variation (CV) of the assays < 8% and < 6%, respectively]. Plasma creatinine levels were measured using a DAX 48 Analyser (Bayer, Basingstoke, England) and serum C-peptide levels by radioimmunoassay (Meginex, Florius, Belgium, CV < 7.5%). The relationship of initial weight, weight change (only found in the first 2 years), current weight, Table2 Weight, HbA1 (mean (SO)) and the numbers of patients seen at 1,2,5 and 10 years of follow-up Table 1 shows clinical details and Table 2 weights and HbAl levels. Height was recorded at diagnosis in only 111 patients. Table 3 shows the prevalence of complications at HbA1 (current and averaged over 5/1 0 years), and current C-peptide levels, to the current prevalence of complications was examined!" using multiple regression analysis, Spearman ranking where data for continuous variables was skewed, and analysis of trend (X 2 ) for non-continuous variables including grade of retinopathy. the 5/10 year annual review examination for patients who had gained weight, were weight stable (fluctuation< 2 kg) or had lost weight by more than 3 kg and then regained it. There was no difference between final and initial weight in men or women, nor any effect of smoking. Weight loss increased with initial weight (r=0.3; P<O.OOOl) but was found only in the first 2 years and only in subjects under 60 years old (N=63). Initial weight loss > 3 kg (and also increased initial weight) related to increased prevalence of albuminuria (P<O.05), a raised creatinine (P<0.05), diastolic hypertension (>90mm mercury, P<O.002) and increased severity of retinopathy. Initial weight correlated with final and 5/10 year average HbAI in women on tablet treatment (N=53, r=0.29, P<O.05). The mean initial weight of those losing > 3 kg (N=34) was 82.4 kg and in those with constant weight, 67.6 kg. An initial bodyweight > 110% of ideal was related to increased prevalence of diastolic hypertension (1"'=0.23, P=0.014) and non-significantly to albuminuria (P=0.06). Body weight related to waist size (1"'=0.57; P<0.005) but not waist/hip ratio. Bodymass index (BMI) related to average HbAlover 5/10 years (P< 0.02) in those with initial recorded height. Average HbA1 for subjects with a BMI of less than 25 throughout was 9.9%, for BMIs greater than 25 and less than 30 was 10.2% and for BMIs > 30, 11.2%.
RESULTS
The severity of retinopathic changes correlated with both longterm glycaemia (5/10 year HbA1 averages) and current HbAl (1"'=0.18, P=0.008), with current systolic blood pressure (1"'=0.17, P=O.OOl) and prevalence of albuminuria (x~=21.6, P=0.002). The prevalence of a raised serum creatinine increased with 5/10 year hyperglycaemia (HbAl > 10.5% as did retinopathy (P<0.002).
Current Cvpeptide levels did not relate to any complication or to control, though they were lowest in those on insulin and lower in those on tablets than on diet (Table 4 ). There were no differences in age or weight at Table 3 The prevalence of complications, 5/10years after diagnosis of type 2 diabetes, with mean initial weights and average HbA1% In relation to weight change during the first 2 years of follow-up On insulin (%) 57.1 28. 6 9.5 4.8 diagnosis between patients in different treatment groups other than the increased initial weight found in those on insulin by the time of their 5/ 10 year review. The significant relationship between average glycaemia and retinopathy seen in the group overall was also found in the sub-group treated with tablets (N=145; r"=0.21; P=0.006); but in men (N=88; r"=0.38; P<O.OOI) and not in the 53 women.
Patients receiving insulin at the end of their 5/10 year follow-up period had an increased prevalence of retinopathy at HbAl levels above 10.5% (X~=3.2; P<O.OI). Peripheral vascular disease was increased in men but not women at HbAl levels > 10.5% in both tablet and insulin treated patients (P< 0.01), as was peripheral neuropathy in the group as a whole (P=0.02), and diastolic hypertension showed increased incidence in patients treated with insulin but not with tablets (P=0.02)
DISCUSSION
The resident population in the district of Tower Hamlets has an annual turnover rate of above 20%. A stable population of patients with type 2 diabetes followed for either 5 years or for 10 years was identified from within the clinic population which had been followed by prospectively planned annual reviews. Weight loss and fluctuations in weight have been described in association with increased hypertension and our findings confirm this, though obesity appears likely to be the significant factor in relation to increased hypertension" and albuminuria. Initial weight loss, though small and found only in the first 2 years after diagnosis, was not, in our patients, associated with improvement in glycaemic control or reduction in incidence of complications by 5/10 years from diagnosis11,12. Increased waist size (but not waist/hip ratio) and initial obesity in women (on tablets) were markers for poor control, hypertension, retinopathy and albuminuria.
C-peptide levels, measured in the fed state at the end of the follow-up period, were likely to reflect insulin secretion since they related simply to the type of treatment needed, and not to control or complications: these findings suggest that residual insulin secretory capacity had no effect on outcome in our patients.
The value of glycaemic control in type 1 diabetes cannot be in doubt and has been strongly reinforced by the DCCT stud y 13-14. Whilst similar relationships are expected in type 2 diabetes, questions remain as to whether the method of achieving control affects outcome. Our findings suggest that glycaemic control was more important than the nature of the treatment used. Whilst the use of insulin was associated with increased hypertension our patients were not randomized to treatment at onset, but treated according to perceived needs. This is, therefore, likely simply to reflect the increased initial weight of subjects treated with insulin by the end of 5/10 years since they had had the worst control. Increased initial weight of those on insulin by 5/10 year follow-up probably reflects both failure of dietary advice and increased efforts to improve glycaemia during the 12 years in which HbA1 levels had been in routine use for all diabetic patients in this clinic at the time of data collection. Whilst providing 1380 patient years of follow-up, our study is small. Further outcomes of the large prospective UKPDS15, using random allocation to different treatments are awaited with interest.
CONCLUSION
Our findings support previous reports suggesting that good glycaemic-control is of value, for reduction in severity of retinopathy in type 2 diabetes 14 , 15 show that poor glycaemic control increases the risk of albuminuria in type 2 diabetes, and suggest that teaching patients with type 2 diabetes that normoglycaemia is of value for the avoidance of complications is appropriate.
APPENDIX
The following are clinical definitions used in the recognition of diabetic complications at annual review in Royal London Hospital diabetic clinics in the last 10 years: Peripheral vascular disease, history of intermittent claudication, ischaemic skin and/or foot ulcers or two or more absent pulses on palpation; peripheral neuropathy, persistent sensory symptoms and/or reduced reflexes, touch, proprioreception or pinprick sensation in feet/legs; benign hypertension, blood pressure (measured with a wide cuff in the obese, to the nearest 2 mmHg; diastole by phase 5) >160/95 aged >60 and >140/90 aged <60; Albuminuria dipstick positive for protein on two or more visits without urinary infection.
Retinopathy 
